PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia

Tendeiro, Ritaa,*; Foxall, Russell B.a,*; Baptista, António P.a; Pinto, Franciscoa; Soares, Rui S.a; Cavaleiro, Ritaa; Valadas, Emíliab; Gomes, Perpétuac,d,e; Victorino, Rui M.M.a,f; Sousa, Ana E.a

doi: 10.1097/QAD.0b013e32835374db
Basic Science

Objective: Hyper-immune activation is a main determinant of HIV disease progression, potentially counter-acted by T-cell inhibitory pathways. Here we investigated, for the first time, inhibitory molecules in HIV-2 infection, a naturally occurring attenuated form of HIV disease, associated with reduced viremia and very slow rates of CD4 T-cell decline.

Design: Programmed death (PD)-1/PD-L1, an important pathway in limiting immunopathology, and its possible relationship with T-cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3), a recently identified inhibitory molecule, were studied in untreated HIV-2 and HIV-1 cohorts, matched for degree of CD4 T-cell depletion, and noninfected individuals.

Methods: Flow cytometric analysis of T-cell expression of PD-1, PD-L1 and TIM-3, combined with markers of cell differentiation, activation, cycling and survival. Statistical analysis was performed using ANOVA, Mann–Whitney/Wilcoxon tests, Spearman's correlations, multiple linear regressions and canonical correlation analysis.

Results: T-cell expression of PD-1 and PD-L1 was tightly associated and directly correlated with CD4 T-cell depletion and immune activation in HIV-2 infection. No such correlation was found for PD-L1 expression in HIV-1-positive patients. Central memory and intermediate memory cells, rather than terminally differentiated T-cells, expressed the highest levels of both PD-1 and PD-L1 molecules. Conversely, TIM-3 expression was independent of T-cell differentiation and dissociated from cell cycling, suggesting distinct induction mechanisms. Importantly, in contrast with HIV-1, no significant increases in TIM-3 expression were found in the HIV-2 cohort.

Conclusions: Our data suggest that PD-1/PD-L1 molecules, rather than markers of T-cell exhaustion, may act as modulators of T-cell immune activation, contributing to the slower course of HIV-2 infection. These data have implications for the design of antiretroviral therapy-complementary immune-based strategies.

Author Information

aUnidade de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa

bClínica de Doenças Infecciosas, Hospital de Santa Maria

cLaboratório de Biologia Molecular, Serviço de Medicina Transfusional, Centro Hospitalar Lisboa Ocidental, Hospital Egas Moniz

dCentro de Malária e Doenças Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa

eCentro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Sul, Caparica

fClínica Universitária de Medicina 2, Centro Hospitalar Lisboa Norte, Hospital Universitário de Santa Maria, Lisboa, Portugal.

*These authors contributed equally to this work.

Correspondence to Ana E. Sousa, MD, PhD, Unidade de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal. Tel: +351 21 7999525; fax: +351 21 7999527; e-mail: asousa@fm.ul.pt

Received 30 January, 2012

Revised 27 February, 2012

Accepted 8 March, 2012

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Article Outline
Back to Top | Article Outline


The hallmark of HIV immunopathogenesis is a hyper-immune activated state that directly correlates with progression to AIDS [1,2]. Since the process of T-cell activation is tightly regulated, resulting from a balance between stimulatory and inhibitory signaling pathways [3], it is plausible that inhibitory molecules play a major role during HIV infection. The programmed death-1 (PD-1) receptor/ligand network is considered one of the main pathways capable of limiting the deleterious effects of inappropriate/exacerbated immune activation [4]. In the context of HIV-1 infection, PD-1 was first described as a cellular exhaustion marker for HIV-specific T-cells, being associated with reduced proliferation and cytokine secretion capacities, and its blockade leading to partial recovery of these functional deficits [5–7]. Recently, however, several groups have suggested that increased PD-1 levels may instead limit tissue damage resulting from chronic immune activation [8,9] and/or persistent antigenemia associated with ongoing viral replication [10–12]. Furthermore, an increasing body of evidence indicates that PD-1 expression alone, may not always be associated with, nor sufficient to characterize an exhausted phenotype, with the co-expression of other inhibitory molecules, like the immunoglobulin superfamily member T-cell immunoglobulin and mucin-domain containing molecule-3 (TIM-3), being essential to define T-cell exhaustion [13–18].

Here we sought to investigate the contribution of the PD-1/PD-L1 pathway and TIM-3 to HIV/AIDS immunopathogenesis through the study of HIV-2 infection, a naturally occurring form of attenuated HIV disease [19]. HIV-2-positive individuals typically feature lower rates of CD4 depletion, reduced amounts of circulating virus and slower disease progression as compared to HIV-1-positive patients [20]. Nevertheless, when matched for the degree of CD4 depletion, both infections feature the same levels of immune activation [2,21]. Data regarding the expression of PD-1, PD-L1 and TIM-3 in HIV-2-positive patients are extremely limited [11]. Investigating the contribution of inhibitory pathways to the slower progression to AIDS observed in HIV-2 infection may provide a rationale for novel therapeutic interventions in HIV/AIDS.

Back to Top | Article Outline


Study populations

The study included 28 HIV-2-positive and 22 HIV-1-positive antiretroviral therapy (ART)-naïve, asymptomatic individuals and 16 seronegative controls (Supplemental Digital Content, Table 1, http://links.lww.com/QAD/A215 for clinical and epidemiological data). Written consent for blood sampling and processing was provided, and the study was approved by the Ethical Board of the Faculty of Medicine of the University of Lisbon.

Back to Top | Article Outline
Flow cytometry

Peripheral blood mononuclear cells (PBMC) were isolated from fresh heparinized blood and surface and/or intracellularly stained, as previously described [22,23]. At least 100 000 events were acquired with a FACSCanto. Analysis was performed using a ‘fluorescence minus one’ strategy with FlowJo software.

Back to Top | Article Outline
Plasma viral load assessment

Viremia was quantified by reverse transcriptase PCR (RT-PCR). Detection thresholds were: 40 RNA copies/ml for HIV-1 (Roche, Basel, Switzerland), and 200 RNA copies/ml for HIV-2, using a previously described in-house assay [24].

Back to Top | Article Outline
Statistical analysis

Statistical analysis was performed using GraphPad Prism v5.00, SPSS v15.0 and MATLAB v7.3. Data were compared using one-way or repeated-measures ANOVA (with the Dunns post-test), followed by Mann–Whitney or Wilcoxon tests, as appropriate; associations were assessed by Spearman's correlation coefficient, multiple linear regressions and canonical correlation analysis. P values below 0.05 were considered significant.

Back to Top | Article Outline


PD-1 expression on T-cells

We compared ART-naive HIV-2 and HIV-1 cohorts matched for CD4 T-cell depletion, with similar levels of T-cell activation, but distinct viremia (Suplemental Digital Content, Table 1). PD-1 expression tended to be higher on both CD4 and CD8 T-cells in HIV cohorts as compared to seronegatives, though HIV-2 featured significantly lower levels within CD8 T-cells than HIV-1 (Fig. 1a). Of note, similar to seronegatives, HIV-2-positive individuals exhibited a significant correlation between PD-1 expression on CD8 and CD4 T-cells, which was not found in the HIV-1 cohort (Supplemental Digital Content, Fig. 1, http://links.lww.com/QAD/A215).

Next, we investigated whether increased PD-1 expression was related to HIV-associated T-cell imbalances [25–27]. PD-1 expression varied with CD8 T-cell differentiation in HIV-2-positive in a similar way to that previously described for HIV-1-positive and seronegative individuals [28,29]. PD-1 levels were lowest on naïve cells, and peaked at the CD45RO+CD27+ stage (Supplemental Digital Content, Fig. 1, http://links.lww.com/QAD/A215), supporting the view that PD-1 up-regulation, rather than being related to terminal T-cell differentiation and exhaustion, may indicate T-cell activation upon antigen encounter. Whilst PD-1 expression was significantly increased on all CD8 T-cell subsets in HIV-1-positive relative to seronegative individuals, this was only observed for CD45RO+CD27+ cells in the HIV-2 cohort. PD-1 expression on CD4 T-cells was similarly linked to cell differentiation, with expression on naive cells being significantly lower in HIV-1-positive and HIV-2-positive as compared to seronegative individuals; conversely, PD-1 expression on memory subsets was increased in both HIV cohorts, although only reaching statistical significance for HIV-1 (Supplemental Digital Content, Fig. 1, http://links.lww.com/QAD/A215).

Programmed death-1 expression on CD4 T-cells was strongly associated with the degree of CD4 depletion and T-cell activation in both HIV cohorts (Table 1 and Supplemental Digital Content, Table 2, http://links.lww.com/QAD/A215). Additionally, significantly increased levels of PD-1 on CD4 and CD8 T-cells were found in viremic as compared to both aviremic HIV-2-positive and seronegative individuals (Supplemental Digital Content, Fig. 2, http://links.lww.com/QAD/A215).

Importantly, no statistically significant correlations were found between PD-1 expression levels on CD8 T-cells and the aforementioned parameters in either HIV cohort, except for CD38 mean fluorescence intensity (MFI) within CD8 T-cells (Table 1).

To investigate which of these factors most strongly influenced PD-1 expression on T-cells, we conducted multiple linear regression (MLR) analyses using combined data from all cohorts. Colinearity analysis revealed associations between CD4 cell counts and T-cell activation levels (data not shown), in agreement with variable inter-dependency [21]. MLR analysis revealed a statistically significant association between PD-1 and human leucocyte antigen DR expressions on CD4 T-cells (β = 0.444, P = 0.030). Moreover, PD-1 expression levels within CD45RO+CD27+ CD8 T-cells were significantly associated with CD38 expression on CD8 T-cells (β = 0.542, P = 0.025) and nearly significantly associated with viremia (β = 0.286, P = 0.055). Moreover, a canonical analysis further supported a role for immune activation in driving increased PD-1 expression on CD4 and CD8 T-cells, as well as an additional contribution of viremia to PD-1 up-regulation on CD8 T-cells (Supplemental Digital Content, Fig. 2, http://links.lww.com/QAD/A215).

Overall, our results suggest that immune activation is the main factor contributing to the increased PD-1 levels during HIV infection. Additionally, they also indicate a role for viremia in PD-1 up-regulation on CD8 T-cells, particularly on the CD45RO+CD27+ subpopulation.

Back to Top | Article Outline
Programmed death-L1 expression on T-cells

Programmed death-L1 can also be up-regulated on T-cells upon activation [30]. Strong direct correlations were observed in HIV-2-positive individuals between PD-L1 expression on CD4 and CD8 T-cells and both the degree of CD4 depletion and T-cell activation (Table 1 and Supplemental Digital Content, Table 2, http://links.lww.com/QAD/A215). Such correlations were largely absent in the HIV-1 cohort and nonexistent in seronegative controls (Table 1), suggesting that PD-L1 expression on T-cells increases specifically during HIV-2 disease progression. This was observed despite the lack of a significant increase in PD-L1 expression levels on CD8 and CD4 T-cells in HIV-2 infection and of a similar differentiation-associated pattern of PD-L1 and PD-1 expression in all cohorts (Supplemental Digital Content, Fig. 3, http://links.lww.com/QAD/A215). Moreover, the expression of PD-L1 and PD-1 expression within CD4 and CD8 T-cells was apparently highly related (Fig. 1b). Overall, our data revealed that HIV-2-positive individuals showed strong correlations between PD-L1 and CD4 depletion and T-cell activation, suggesting that the strict control of PD-L1 expression may contribute to the slow HIV-2 disease progression.

Back to Top | Article Outline
TIM-3 expression on T-cells

In order to investigate TIM-3 expression in HIV-2 infection and its relationship with PD-1/PD-L1, we studied additional age-matched cohorts of ART-naive HIV-1-positive and HIV-2-positive individuals with more than 300 CD4 T-cells/μl, and seronegative controls (Supplemental Digital Content, Table 3, http://links.lww.com/QAD/A215 for clinical and epidemiological data).

The mechanisms regulating TIM-3 expression remain poorly understood [31–34]. Regarding the CD8 T-cell subset, the frequency of TIM3+PD1+ cells was very low (Fig. 1c) and, in contrast to PD-1, TIM-3 expression seemed to be independent of T-cell differentiation in all cohorts (Supplemental Digital Content, Fig. 4, http://links.lww.com/QAD/A215).

TIM-3 expression was higher in HIV-1-positive patients as compared to both HIV-2-positive and seronegative individuals on CD8 and CD4 T-cells, although only reaching significance in comparison with the latter (Fig. 1d).

Of note, the contribution of TIM-3+ cells to cycling T-cells was negligible in all cohorts in marked contrast to PD-1+ cells (Fig. 1e), which represented a significant proportion of cycling T-cells, particularly in the HIV-1 cohort, further supporting the requirement of T-cell receptor stimulation for PD-1 up-regulation.

Conversely, both PD-1 and TIM-3 expression seemed to impact on CD8 T-cell survival, as previously described [35,36], as indicated by the inverse correlation found with Bcl-2 expression levels within CD8 T-cells (Fig. 1f). No such correlations were found on CD4 T-cells (Fig. 1f).

We also confirmed that the above reported imbalances in the expression of inhibitory molecules were unrelated to regulatory CD4 T-cells (Treg), defined by FoxP3 expression (Supplemental Digital Content, Fig. 5, http://links.lww.com/QAD/A215) that have been reported to express high levels of PD-1 and TIM-3 [37,38].

Overall, our data showed that over-representation of a TIM-3+ population in T-cells, particularly within the CD8 subset, was much more marked in HIV-1 than in HIV-2 infection. Moreover, TIM-3 expression was apparently independent of T-cell differentiation and disassociated from cell cycling.

Back to Top | Article Outline


We report here, for the first time, that HIV-2 infection was associated with increased PD-1/PD-L1 expression on both CD4 and CD8 T-cells, in direct correlation with the degree of CD4 depletion and T-cell activation. PD-1 up-regulation occurred in the majority of untreated HIV-2-positive individuals despite their low to undetectable viremia. We also found strong correlations between the expression of its main ligand, PD-L1, within both CD4 and CD8 T-cells, and the degree of CD4 depletion and immune activation that were exclusive to the HIV-2 cohort, in agreement with our previous data on plasmacytoid dendritic cells [23]. The expression of these inhibitory markers seemed to be mainly driven by immune activation, the major determinant of the rate of CD4 T-cell loss and AIDS progression, both in HIV-1 and HIV-2 infections [5,8,39,40]. Our data suggest that PD-1/PD-L1 up-regulation may reflect an attempt to limit immunopathology, hence contributing to a more benign course of HIV infection.

We showed that HIV-2-positive individuals did not feature a significant up-regulation of TIM-3, in contrast to the HIV-1 cohort which exhibited an over-expression of TIM-3 within CD4 and CD8 T-cells, as previously reported [15,16], even in early-stage disease. TIM-3 expression was dissociated from PD-1 expression, and markers of cell differentiation and cell cycling, but inversely correlated with the levels of the antiapoptotic molecule Bcl-2 on CD8 T-cells. Thus, PD-1 and TIM-3 may be differentially regulated, resulting in their expression by functionally distinct T-cell populations. Overall, we found no significant changes in TIM-3 expression in HIV-2-positive individuals, in contrast to its up-regulation throughout HIV-1 infection, suggesting a role of TIM-3 in the protected HIV-2 disease course.

In conclusion, we showed that, during the relatively benign course of HIV-2 infection, there was a progressive increase in the expression of PD-1 and PD-LI within CD4 and CD8 T-cells but not of TIM-3. Our data suggest that the PD-1/PD-L1 pathway may counter-act the hyper-immune activation associated with AIDS progression with implications for the design of ART-complementary immune-based strategies.

Back to Top | Article Outline


We gratefully acknowledge the clinical collaboration of the following colleagues: A. Ribeiro, F. Antunes, M. Doroana, M. Lucas, and S. Sousa.

Author contributions: R.T., R.B.F. and A.P.B. designed and performed experiments, analysed data and wrote the paper; F.P. performed statistical analysis; R.S.S., R.C., and P.G. performed experiments; E.V. and R.M.M.V. contributed to the design of the study and data interpretation; A.E.S. designed the research and wrote the paper.

Financial support: The work was supported by grants from ‘Fundação para a Ciência e a Tecnologia’ (FCT) and by ‘Programa Operacional Ciência e Inovação 2010’ (POCI2010), as well as from Fundação Calouste Gulbenkian to A.E.S. R.T., R.B.F., R.S.S., and R.C. received scholarships from FCT.

Back to Top | Article Outline
Conflicts of interest

The authors have no conflicting financial interests.

Back to Top | Article Outline


1. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22:439–446.
2. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat Med 2002; 8:319–323.
3. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999; 77:1–10.
4. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111–122.
5. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350–354.
6. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198–1202.
7. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281–2292.
8. Hokey DA, Johnson FB, Smith J, Weber JL, Yan J, Hirao L, et al. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol 2008; 38:1435–1445.
9. Sadagopal S, Lorey SL, Barnett L, Sutherland D, Basham R, Erdem H, et al. Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. J Virol 2010; 84:131–140.
10. Bucks CM, Norton JA, Boesteanu AC, Mueller YM, Katsikis PD. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol 2009; 182:6697–6708.
11. Leligdowicz A, Onyango C, Yindom LM, Peng Y, Cotten M, Jaye A, et al. Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection. Eur J Immunol 2010; 40:1963–1972.
12. Salisch NC, Kaufmann DE, Awad AS, Reeves RK, Tighe DP, Li Y, et al. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol 2010; 184:476–487.
13. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175–2186.
14. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107:14733–14738.
15. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205:2763–2779.
16. Kassu A, Marcus RA, D'Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R, et al. Regulation of virus-specific CD4(+) T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185:3007–3018.
17. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J Exp Med 2010; 207:2187–2194.
18. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010; 40:2493–2505.
19. Popper SJ, Sarr AD, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116–1121.
20. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457–468.
21. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400–3406.
22. Foxall RB, Albuquerque AS, Soares RS, Baptista AP, Cavaleiro R, Tendeiro R, et al. Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS 2011; 25:1961–1970.
23. Cavaleiro R, Baptista AP, Soares RS, Tendeiro R, Foxall RB, Gomes P, et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog 2009; 5:e1000667.
24. Soares RS, Tendeiro R, Foxall RB, Baptista AP, Cavaleiro R, Gomes P, et al. Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol 2011; 85:2429–2438.
25. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12:289–295.
26. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410:106–111.
27. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004; 103:966–972.
28. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, Appay V. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007; 21:2005–2013.
29. Rosignoli G, Lim CH, Bower M, Gotch F, Imami N. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol 2009; 157:90–97.
30. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365–1369.
31. Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos-Peyton CA, Glimcher LH, Kuchroo VK. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol 2010; 40:859–866.
32. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245–1252.
33. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L, Chen ZK. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol 2007; 250:68–74.
34. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009; 39:2492–2501.
35. Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, Hill BJ, et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 2009; 183:1120–1132.
36. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 2010; 6:e1000882.
37. Lim A, French MA, Price P. CD4+ and CD8+ T cells expressing FoxP3 in HIV-infected patients are phenotypically distinct and influenced by disease severity and antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:248–257.
38. Boenisch O, D’Addio F, Watanabe T, Elyaman W, Magee CN, Yeung MY, et al. TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol 2010; 185:5806–5819.
39. Holm M, Pettersen FO, Kvale D. PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res 2008; 6:49–58.
40. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109:4671–4678.

HIV pathogenesis; HIV-2; immune activation; PD-1; PD-L1; T-cell subsets; TIM-3

Supplemental Digital Content

Back to Top | Article Outline
© 2012 Lippincott Williams & Wilkins, Inc.